Company Description
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at-home administration without medical professional assistance.
Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use.
The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures.
In addition, it provides WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing.
The company sells its products directly to patients, as well as through distributor agreements in the United States, Europe, Australia, Israel, New Zealand, and internationally.
The company was formerly known as NanoVibronix, Inc. and changed its name to ENvue Medical, Inc. in December 2025.
The company was incorporated in 2003 and is based in Tyler, Texas.
| Country | United States |
| Founded | 2003 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Doron Besser |
Contact Details
Address: 969 Pruitt Ave Tyler, Texas 77569 United States | |
| Phone | 914 233 3004 |
| Website | envuemed.com |
Stock Details
| Ticker Symbol | FEED |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001326706 |
| CUSIP Number | 63008J884 |
| ISIN Number | US63008J8844 |
Key Executives
| Name | Position |
|---|---|
| Dr. Doron Robert Besser M.D. | Chief Executive Officer, President and Director |
| Nicole Fernandez-McGovern CPA | Interim Chief Financial Officer |
| Rita Silberberg | Executive Vice President of Finance, Chief Accounting Officer and Corporate Secretary |
| Lindsey Harrison | Vice President of Sales |